Beirne Wealth Consulting Services, LLC Lineage Cell Therapeutics, Inc. Transaction History
Beirne Wealth Consulting Services, LLC
- $248 Billion
- Q2 2024
A detailed history of Beirne Wealth Consulting Services, LLC transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Beirne Wealth Consulting Services, LLC holds 45,000 shares of LCTX stock, worth $40,950. This represents 0.02% of its overall portfolio holdings.
Number of Shares
45,000
Previous 45,000
-0.0%
Holding current value
$40,950
Previous $66.6 Million
32.61%
% of portfolio
0.02%
Previous 0.03%
Shares
3 transactions
Others Institutions Holding LCTX
# of Institutions
121Shares Held
94.3MCall Options Held
31.3KPut Options Held
400-
Broadwood Capital Inc New York, NY41.7MShares$37.9 Million3.19% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$8.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.47MShares$7.71 Million0.0% of portfolio
-
Defender Capital, Llc.4.97MShares$4.53 Million1.77% of portfolio
-
Logos Global Management LP San Francisco, CA4.7MShares$4.28 Million0.44% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $154M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...